Overview

Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis

Status:
Completed

Trial end date:
2010-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of E3810 tablets in patients with Proton Pump Inhibitor-resistant reflux esophagitis.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Rabeprazole